Form 4: Travere Therapeutics Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Travere Therapeutics, Inc. reports an automatic equity grant to Director Roy D. Baynes under the company's incentive plan.
Summary
- Director Roy D. Baynes received an automatic equity grant of 4,000 shares of common stock on May 19, 2026.
- This grant was made under the Issuer's 2018 Equity Incentive Plan, as amended, as part of the non-employee director compensation program.
- The equity award vests over a one-year period.
- Additionally, a stock option to buy 12,000 shares of common stock was granted on May 19, 2026, with an exercise price of $42.26.
- This option is exercisable starting May 19, 2027, and expires on May 19, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine director compensation through equity awards rather than significant financial performance or strategic changes.
Positives
- Director compensation is being provided through equity awards, aligning director interests with shareholders.
- The grant of stock options indicates a long-term incentive structure for the director.
- The equity award vests over one year, providing a relatively short-term incentive.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding future financial performance. It solely reports on a director's equity awards.
Industry Context
StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and pharmaceutical sectors, including companies like Travere Therapeutics, to attract and retain experienced leadership and align their incentives with long-term shareholder value.
Stakeholder Impact
- Shareholders: The equity awards align director interests with shareholder value, potentially leading to better long-term decision-making.
- Employees: The compensation structure for directors may indirectly influence overall employee compensation strategies.
- Management: The grant of options suggests confidence in the company's future performance, which can motivate management.
Key Dates
| Date | Description |
|---|---|
| 05/19/2026 | Earliest transaction date, date of equity grant and stock option grant. |
| 05/19/2027 | Date stock option becomes exercisable. |
| 05/19/2036 | Expiration date of stock option. |
| 05/21/2026 | Date of filing signature. |
Keywords
Travere Therapeutics, TVTX, Form 4, Equity Grant, Stock Options, Director Compensation, SEC Filing, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.